Efficacy and Safety of Rivastigmine in Patients With Traumatic Brain Injury and Cognitive Impairment
This study is designed to investigate the efficacy and safety of rivastigmine compared with placebo in patients with traumatic brain injury and cognitive impairment...
Brief Summary
Official Title: “Efficacy and Safety of Rivastigmine in Patients With Traumatic Brain Injury and Cognitive Impairment”
This study is designed to investigate the efficacy and safety of rivastigmine compared with placebo in patients with traumatic brain injury and cognitive impairment.
- Study Type: Interventional
- Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
- Study Primary Completion Date: May 2005
Intervention(s) in this Clinical Trial
- Drug: Rivastigmine
Outcome Measures for this Clinical Trial
Primary Measures
- 20 week's treatment with rivastigmine on selective attention compared with placebo in patients with TBI and cognitive impairment
Secondary Measures
- Safety of rivastigmine
- Change from baseline to week 20 in cognitive functioning including selective attention, memory, executive function, and global clinical rating
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Traumatic brain injury confirmed by available brain imaging (CT or MRI) and be at least 52 weeks post injury
- Neuropsychologic disturbances indicated by: impaired memory (reduction of below 1 standard deviation (SD) of the mean on the California Verbal Learning Test (CVLT) and impaired executive function (reduction of below 1 standard deviation (SD) of the mean on the Verbal Memory Learning Test (VLMT) and Tower of London Test (ToL) and impaired attention (reduction of below 1 standard deviation (SD) of the mean on the Test
- Battery for Attentional Performance (TAP)
- Be required to have had sufficient education to read, write, and effectively communicate
- Be cooperative, able to ingest oral medication, and able to complete all aspects of the study and capable of doing so, either alone or with the aid of a responsible caregiver according to the investigator's judgement
Exclusion Criteria:
- A current diagnosis of cerebrovascular disease, any primary neurodegenerative disorder, or any other causes of neuropsychologic disturbances
- A current diagnosis of active, uncontrolled seizure disorder or major depression, or any other diagnosis that may interfere with the patient's response to study medication
- An advanced, severe or unstable disease of any type that may interfere with efficacy evaluations
- Female patients with child-bearing potential who are breast-feeding, pregnant or not practicing non-hormonal contraception
- Other protocol-defined inclusion/exclusion criteria may apply.
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: 65 Years
Clinical Trial Investigator Information
Lead Investigator: Novartis Industry
Overall Clinical Trial Officials and Contacts
Novartis Pharma Study Director Novartis Pharmaceuticals
Additional Information
Information obtained from ClinicalTrials.gov on February 09, 2012
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00171795
Study ID Number: CENA713BDE01
ClinicalTrials.gov Identifier: NCT00171795
Health Authority: Germany: Federal Institute for Drugs and Medical Devices
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00171795
